Flugen, Inc. Raises $2M More, Provides Update on Phase I Trial
FluGen has raised another $2 million from investors to support current and planned clinical trials of an experimental universal influenza vaccine that the Madison, WI-based startup is developing.
Paul Radspinner, who co-founded FluGen in 2007 and serves as the company’s president and CEO, says the latest funding is an addition to the $9.4 million funding round FluGen announced in 2015.
Paul Radspinner, who co-founded FluGen in 2007 and serves as the company’s president and CEO, says the latest funding is an addition to the $9.4 million funding round FluGen announced in 2015.